Evaluating portal vein stenting for patients with gastrointestinal cancers and vein narrowing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and effectiveness of portal vein stenting in patients suffering from portal vein stenosis associated with gastrointestinal cancers. It involves two cohorts: one that receives stenting and completes quality of life assessments, and another that is reviewed retrospectively without stenting. The study will measure stent patency, clinical success duration, and impacts on liver volumes and nutritional status. The goal is to gather data that could enhance patient care and outcomes in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* COHORT A: All patients will undergo initial staging and treatment as per the institution standard of care. Patients will be considered eligible for porto-mesenteric venous stenting (PVS) if:

  * There is \> 75% porto-mesenteric venous stenosis in either main portal vein (PV), left PV, right PV, or the superior mesenteric vein (SMV), even in absence of symptoms of portal hypertension
  * Patients presented with any degree of vascular narrowing of said vessels and symptomatic portal hypertension including variceal bleeding, refractory ascites, abdominal pain, intestinal edema, or diarrhea after exclusion of tumor-related causes as direct tumor invasion or peritoneal dissemination
* COHORT B: Patients who have thrombosis/stenosis of the main portal vein but who did not undergo stenting

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Joshua D Kuban — M.D. Anderson Cancer Center
• Study coordinator: Joshua D. Kuban
• Email: jdkuban@mdanderson.org
• Phone: 713-745-0944

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vasodilator Therapy to Reduce Vascular Side Effects in GI Cancer Patients on Fluoropyrimidines

  This study tests whether vasodilator drugs (isossorbide mononitrate or diltiazem) or placebo can reduce blood vessel toxicity for adults with gastrointestinal cancers treated with fluoropyrimidine chemotherapy.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07456852

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Using fucoidan to prevent fatigue in cancer patients undergoing chemotherapy

  This study tests if a seaweed supplement called fucoidan can help cancer patients undergoing chemotherapy feel less tired.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06855524

• Understanding risk factors and genetic changes in biliary tree cancers

  This study is trying to find out what causes biliary tree cancers and how genetic changes can help doctors understand treatment responses in patients with these cancers.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05179486

• Comparing 2-hour and 6-hour oxaliplatin infusions for gastrointestinal cancer treatment

  This study is testing whether giving oxaliplatin over 2 hours instead of 6 hours can help people with gastrointestinal cancer experience less nerve damage while still getting effective treatment.

  Recruiting at 3 sites Phase 2 Emory University · Atlanta, Georgia and 2 other locations · NCT03800693

• Collecting data on side effects of proton therapy for cancer treatment

  This study is trying to learn about the side effects that cancer patients experience after receiving proton therapy to help improve future treatments.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT00991094

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.